WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
SpaceX Stock Rebounds After Sharp Selloff, But Valuation Concerns Persist 
Micron Stock Surges on Strong AI Demand, Record Revenue, and Bullish Q4 Forecast 
Anthropic AI Model Uncovers Vulnerabilities in Classified U.S. Government Systems During Security Test 
SpaceX Stock Plunges 16% as KeyBanc Warns Valuation May Be Overstretched 
Tencent Reviews Marvelous Stake as Gaming Giant Reassesses Global Investment Strategy 
Trump’s Quantum Push Lifts IBM Stock as CEO Arvind Krishna Receives White House Praise 
NTSB Investigates Boston Logan Airport Near-Miss Between Delta and American Airlines Jets 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
Alphabet Stock Slides as AI Talent Exodus and SpaceX Losses Shake Investor Confidence 
Meta Reportedly Developing ‘Arena’ Prediction Market App to Rival Polymarket and Kalshi 
California Drivers Sue BP, Walmart, 7-Eleven Over Alleged AI Gas Price Fixing 
Bain Capital Nears Deal for Majority Stake in Volkswagen Marine Engine Unit Everllence 
SK Hynix Moves Closer to New York ADR Listing Amid AI Chip Boom 
Trump Orders DOJ Investigation Into Exxon, Chevron Over High Gas Prices 
Meta Pauses Employee Activity Tracking Program Over Data Security Concerns 
HAMPTON, N.J., Feb. 18, 2016 -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) will release fourth quarter and year-end 2015 financial results on Thursday, February 25, 2016 before the U.S. financial markets open. Celldex executives will host a conference call at 8:00 a.m. EST on the same day to discuss 2015 financial and business results and to provide an update on key 2016 objectives.
The conference call and presentation will be webcast live over the Internet and can be accessed by going to the "Events & Presentations" page under the "Investors & Media" section of the Celldex Therapeutics website at www.celldex.com. The call can also be accessed by dialing (866) 743-9666 (within the United States) or (760) 298-5103 (outside the United States). The passcode is 50465153.
A replay of the call will be available approximately two hours after the live call concludes through March 3, 2016. To access the replay, dial (855) 859-2056 (within the United States) or (404) 537-3406 (outside the United States). The passcode is 50465153. The webcast will also be archived on the Company's website.
About Celldex Therapeutics, Inc.
Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response. Visit www.celldex.com.
Contact Sarah Cavanaugh Vice President of Investor Relations & Corp Communications Celldex Therapeutics, Inc. (781) 433-3161 [email protected] Charles Liles Manager of Investor Relations & Corp Communications Celldex Therapeutics, Inc. (781) 433-3107 [email protected]
